FDA supplemental approval: Hydrocodone Bitartrate AND Acetaminophen (REMS)

AI Summary

The FDA approved a supplemental REMS application for hydrocodone bitartrate and acetaminophen tablets (7.5 mg and 10 mg hydrocodone formulations) sponsored by Amneal Pharmaceuticals NY, effective 18 June 2026. This is a regulatory compliance action that establishes or modifies risk management requirements for the product; the record does not contain clinical trial results, efficacy data, or safety evidence.

Plain-language summary

FDA supplemental approval of a REMS (Risk Evaluation and Mitigation Strategy) for an existing combination opioid–acetaminophen product; this is a regulatory action, not a clinical trial, and does not report efficacy or safety data.

Reported figures

Quoted from the source exactly as published.

Clinical bottom line

This regulatory record does not report clinical efficacy, safety, or comparative benefit data. Clinicians should refer to the approved REMS requirements and product labeling for prescribing and monitoring guidance; no new clinical evidence is presented here.

Caveats

• This record does not contain clinical trial results, safety data, or efficacy evidence.
• No information on the specific content or requirements of the approved REMS is provided.
• No patient population, indication, or clinical outcome data are reported.
• Generalizability and clinical impact cannot be assessed from a regulatory approval record alone.

Evidence assessment

Graded across the dimensions that decide whether you should act, each from what the source actually supports. There is no single score, and where a dimension was not assessed it says so.

Follow from this

Taken from the source record, never inferred. Follow any of these and new work involving them reaches your briefing.